Bio-Solutions Corporation Completes Initial Production of Diabetic Product, Type2 Defense
(firmenpresse) - SAN ANTONIO, TEXAS -- (Marketwired) -- 06/27/13 -- Bio-Solutions Corporation (OTCBB: BISU)(PINKSHEETS: BISU) is pleased to announce that the company has completed its initial order of the diabetic product Type2 Defense with Nutricap Labs located in Farmingdale, New York. The successful completion of the initial production order is an important milestone for Bio-Solutions Corporation. The company is now positioned to distribute final product samples to the different groups that are presently considering endorsing the Type2 Defense product and begin set-up of proper distribution channels for the product.
Type2 Defense is a preventative supplement for people who are diabetic or who are pre-diabetic. The product helps regulate blood sugar and blood pressure levels in diabetic and pre-diabetic subjects, especially for those who are insulin-resistant. "The company recognizes the diabetic epidemic that is happening in this country and throughout the world. We are excited to now be able to offer such a dynamic nutritional supplement that supports healthy living in the diabetic community" says CEO Bill Gallagher.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. All statements which address actual results could differ materially from those expressed or implied in forward-looking statements. These statements are made on the basis of management's views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as management "believes," "expects," "anticipates," "foresees," "forecasts," "estimates" or other words or phrases of similar import. Similarly, statements in this release that describe the Company's business strategy, outlook, objectives, plans, intentions or goals also are forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that the ability to attract clients and generate business may be affected by a decline in the Company's financial ratings, the competitive environment, the Company's ability to raise sufficient capital to meet the collateral requirements associated with its current business and to fund the Company's continuing operations and changes in market conditions.
Contacts:
William Gallagher
Chief Executive Officer
Bio-Solutions Corporation
210-218-4475
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 27.06.2013 - 06:45 Uhr
Sprache: Deutsch
News-ID 1240966
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
SAN ANTONIO, TEXAS
Phone:
Kategorie:
Biotech
Anmerkungen:
Diese Pressemitteilung wurde bisher 134 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Bio-Solutions Corporation Completes Initial Production of Diabetic Product, Type2 Defense
"
steht unter der journalistisch-redaktionellen Verantwortung von
Bio-Solutions Corp. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
